News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Al's Comment:

 This is a very important article.  Although a small sample, it opens the door to using a BRAF inhibitor for brain tumors that have the BRAF V-600 mutation. Note that this shouldn't be used in other mutations of BRAF, only the V-600 mutation. They found that using these drugs may actually speed up the tumor if they do not have the V-600 mutation.


Posted on: 04/12/2018

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

https://www.ncbi.nlm.nih.gov/pubmed/29632053

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740